Clinical trial NCT05080868: Infantile Hemangioma With Minimal or Arrested Growth : Epidemiology, Clinical Characteristics and Evolution
Official title: Comparing Epidemiological and Clinical Characteristics of Infantile Hemangioma With Minimal or Arrested Growth (IH-MAG) and Classic Infantile Hemangioma : a Retrospective Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Hemangioma, Capillary
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2021-10-18
Enrollment: 224
Sex: ALL
Minimum age (years): 1
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: - Children between 0 and 18 years old followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020 presenting with one or more infantile hemangioma

Brief summary: Infantile hemangioma (IH) is the most common vascular tumor of infancy, characterized by its clinical history. Absent at birth or present under the form of a premonitory mark, they display a rapid proliferative phase starting in the first weeks of life. Then, after a plateau phase, they slowly involute. However, a subtype of IH named "abortive", "minimal or arrested growth", "reticular" or "telangiectatic" hemangioma differs from typical IH because it doesn't have a proliferative component, or only a minimal one. This subtype of hemangioma has been recently described and data are lacking regarding its proportion among infantile hemangioma and its differences with "classic" infantile hemangioma. The aim of this study is to estimate the proportion of abortive hemangioma among infantile hemangioma. Also, the investigators aim to compare the clinical characteristics of "classic" infantile hemangiomas and abortive hemangiomas. Lastly, investigators wished to study the evolution of abortive hemangioma.


Eligibility criteria: Inclusion Criteria:

* Children between 0 and 18 years old
* Followed in the dermatology department of CHRU de Nancy between January 2014 and December 2020
* Presenting with one or more infantile hemangioma

Exclusion Criteria:

- Those whoes guardian does not want his data to be collected in this study

Primary outcomes:
measure: Proportion of abortive hemangioma among infantile hemangioma
timeFrame: baseline
Secondary outcomes:
measure: To compare the epidemiological characteristics between infantile hemangioma and abortive hemangioma : sex
timeFrame: baseline
measure: To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : prematurity
timeFrame: baseline
measure: To compare the epidemiological characteristics between infantile hemangiomas and abortive hemangiomas : birthweight
timeFrame: baseline
measure: To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : localization
timeFrame: baseline
measure: To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : treatment
timeFrame: baseline
measure: To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : complications
timeFrame: baseline
measure: To compare the clinical characteristics between infantile hemangiomas and abortive hemangiomas : size
timeFrame: baseline
measure: To study the evolution of abortive hemangioma : erythematous macule
timeFrame: through study completion, an average of 4 years
measure: To study the evolution of abortive hemangioma : papules of proliferation
timeFrame: through study completion, an average of 4 years
measure: To study the evolution of abortive hemangioma : telangiectasias
timeFrame: through study completion, an average of 4 years
measure: To study the evolution of abortive hemangioma : halo of vasoconstriction
timeFrame: through study completion, an average of 4 years
measure: To study the evolution of abortive hemangioma : areas of vasoconstriction
timeFrame: through study completion, an average of 4 years
measure: To study the evolution of abortive hemangioma : dilated veins
timeFrame: through study completion, an average of 4 years
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHRU de Nancy
state: Grand-Est
Study officials:
affiliation: Central Hospital, Nancy, France
name: BURSZTEJN Anne-Claire, MD, PhD
role: STUDY_DIRECTOR
References: